Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
June 25, 2013 -- Shanghai Pharmaceuticals purchased another 11% of Shanghai Sunway Biotech, bringing its total holdings in the company to 81%. In 2005, Sunway was granted CFDA approval of a gene therapy treatment, using an oncolytic adenovirus as a delivery vehicle, for late-stage refractory nasopharyngeal cancer. Shanghai Pharma paid 1 million RMB ($160,000) for its purchase of the 11% stake. More details....
Stock Symbols: (SHA: 601607)
Help employers find you! Check out all the jobs and post your resume.
by Richard Daverman, PhD
June 25, 2013 -- Shanghai Pharmaceuticals purchased another 11% of Shanghai Sunway Biotech, bringing its total holdings in the company to 81%. In 2005, Sunway was granted CFDA approval of a gene therapy treatment, using an oncolytic adenovirus as a delivery vehicle, for late-stage refractory nasopharyngeal cancer. Shanghai Pharma paid 1 million RMB ($160,000) for its purchase of the 11% stake. More details....
Stock Symbols: (SHA: 601607)
Help employers find you! Check out all the jobs and post your resume.
